This document summarizes targeted therapy options for BRAF V600-mutant melanoma. Approximately 50% of melanomas harbor BRAF mutations. Clinical trials have shown that the BRAF inhibitors vemurafenib and dabrafenib, as well as the MEK inhibitor trametinib, provide significant improvements in response rates, progression-free survival, and overall survival compared to chemotherapy when used as initial therapies for BRAF V600-mutant metastatic melanoma. However, resistance to these targeted agents typically develops within 6-8 months. Mechanisms of resistance include bypass pathway activation or upregulation. Combination strategies of BRAF and MEK inhibitors are being studied to delay or prevent resistance.
Este documento describe el abordaje genético del cáncer de mama y ovario hereditario. Primero, selecciona pacientes para el estudio basado en factores de riesgo familiares e individuales. Luego, utiliza técnicas de secuenciación masiva para identificar mutaciones en los genes BRCA1 y BRCA2, incluyendo mutaciones puntuales, deleciones, inserciones y reordenamientos. Finalmente, discute la interpretación de las variantes encontradas y otros síndromes hereditarios asociados con cáncer de mama y ovario.
El documento presenta información sobre el síndrome de alergia oral (SAO), también conocido como síndrome de polen-alimento (PFAS). El SAO se caracteriza por síntomas orofaríngeos provocados por la exposición a alérgenos alimentarios específicos. Se discute la epidemiología, factores de riesgo, mecanismos fisiopatológicos como la reactividad cruzada entre proteínas de plantas, y las principales familias de proteínas alergénicas como las profilinas y las PR-10 que causan
Recent progressing approaches to improve the efficiency of CAR-T cell immunotherapy against solid tumors.
1. Promoting CAR-T cell trafficking and infiltration at tumor sites through approaches like engineering CAR-T cells to express the enzyme heparanase to degrade tumor extracellular matrix, or incorporating chemokine receptor genes into CAR-T cells to guide them to tumor locations.
2. Preventing tumor immune escape by blocking immune checkpoint molecules like PD-1 and CTLA-4 that inhibit CAR-T cells, or knocking out the adenosine 2A receptor to reduce CAR-T cell dysfunction.
3. Developing bi-specific CAR-T cells targeting two different tumor antigens to reduce immune escape, and
Gastric cancer debate adjuvant chemoradiotherapyMohamed Abdulla
This document summarizes a presentation on adjuvant chemo-radiotherapy for gastric cancer. It discusses key facts about gastric cancer incidence and survival rates. It reviews clinical trials like Intergroup 0116 and ARTIST that showed improved survival with adjuvant chemoradiotherapy for patients with positive lymph nodes or incomplete nodal dissection. The presentation concludes that multimodal treatment including surgery and adjuvant therapy is superior to single modality treatment, and that radiation therapy may improve outcomes for patients with intestinal-type cancer and positive lymph nodes.
Este documento resume la epidemiología, etiología, patogenia, clasificación, factores pronósticos y tratamiento del cáncer de mama. Explica que el cáncer de mama es el tipo más común de cáncer no cutáneo en mujeres y que factores como la edad, la raza y la historia familiar afectan el riesgo. Describe las diferentes clasificaciones histológicas de cáncer de mama como carcinoma ductal y lobulillar in situ y carcinoma invasivo, y los subtipos luminales A y B. Finalmente, resume los fact
Abordaje de Toxicidades en el tratamiento con inmunoterapia e inhibidores: Po...Virginia Salinas
Presentación realizada en la I Jornada de Formación
en Enfermería Oncológica en Bilbao, con el lema: Avanzando en el Cuidado Oncológico. Aprendiendo juntos. La Mesa abordaba los nuevos tratamientos, y el manejo de toxicidades, y tuvo lugar el viernes 18 de mayo de 2018.
El mieloma múltiple es una neoplasia de la médula ósea caracterizada por la proliferación de células plasmáticas anormales que producen una proteína monoclonal. Provoca dolor óseo, anemia y falla renal. No tiene una causa conocida pero se cree que involucra defectos en la inmunorregulación. Su tratamiento incluye quimioterapia como melfalán y prednisona.
This document summarizes information about immunotherapy for non-small cell lung cancer (NSCLC). It provides data on key clinical trials that evaluated immunotherapy drugs like nivolumab and pembrolizumab in previously treated NSCLC. It shows the efficacy results including overall survival benefits from these trials compared to chemotherapy. Long-term survival outcomes are also presented from pooled analyses of nivolumab trials with over 3 years of follow-up data.
Este documento describe el abordaje genético del cáncer de mama y ovario hereditario. Primero, selecciona pacientes para el estudio basado en factores de riesgo familiares e individuales. Luego, utiliza técnicas de secuenciación masiva para identificar mutaciones en los genes BRCA1 y BRCA2, incluyendo mutaciones puntuales, deleciones, inserciones y reordenamientos. Finalmente, discute la interpretación de las variantes encontradas y otros síndromes hereditarios asociados con cáncer de mama y ovario.
El documento presenta información sobre el síndrome de alergia oral (SAO), también conocido como síndrome de polen-alimento (PFAS). El SAO se caracteriza por síntomas orofaríngeos provocados por la exposición a alérgenos alimentarios específicos. Se discute la epidemiología, factores de riesgo, mecanismos fisiopatológicos como la reactividad cruzada entre proteínas de plantas, y las principales familias de proteínas alergénicas como las profilinas y las PR-10 que causan
Recent progressing approaches to improve the efficiency of CAR-T cell immunotherapy against solid tumors.
1. Promoting CAR-T cell trafficking and infiltration at tumor sites through approaches like engineering CAR-T cells to express the enzyme heparanase to degrade tumor extracellular matrix, or incorporating chemokine receptor genes into CAR-T cells to guide them to tumor locations.
2. Preventing tumor immune escape by blocking immune checkpoint molecules like PD-1 and CTLA-4 that inhibit CAR-T cells, or knocking out the adenosine 2A receptor to reduce CAR-T cell dysfunction.
3. Developing bi-specific CAR-T cells targeting two different tumor antigens to reduce immune escape, and
Gastric cancer debate adjuvant chemoradiotherapyMohamed Abdulla
This document summarizes a presentation on adjuvant chemo-radiotherapy for gastric cancer. It discusses key facts about gastric cancer incidence and survival rates. It reviews clinical trials like Intergroup 0116 and ARTIST that showed improved survival with adjuvant chemoradiotherapy for patients with positive lymph nodes or incomplete nodal dissection. The presentation concludes that multimodal treatment including surgery and adjuvant therapy is superior to single modality treatment, and that radiation therapy may improve outcomes for patients with intestinal-type cancer and positive lymph nodes.
Este documento resume la epidemiología, etiología, patogenia, clasificación, factores pronósticos y tratamiento del cáncer de mama. Explica que el cáncer de mama es el tipo más común de cáncer no cutáneo en mujeres y que factores como la edad, la raza y la historia familiar afectan el riesgo. Describe las diferentes clasificaciones histológicas de cáncer de mama como carcinoma ductal y lobulillar in situ y carcinoma invasivo, y los subtipos luminales A y B. Finalmente, resume los fact
Abordaje de Toxicidades en el tratamiento con inmunoterapia e inhibidores: Po...Virginia Salinas
Presentación realizada en la I Jornada de Formación
en Enfermería Oncológica en Bilbao, con el lema: Avanzando en el Cuidado Oncológico. Aprendiendo juntos. La Mesa abordaba los nuevos tratamientos, y el manejo de toxicidades, y tuvo lugar el viernes 18 de mayo de 2018.
El mieloma múltiple es una neoplasia de la médula ósea caracterizada por la proliferación de células plasmáticas anormales que producen una proteína monoclonal. Provoca dolor óseo, anemia y falla renal. No tiene una causa conocida pero se cree que involucra defectos en la inmunorregulación. Su tratamiento incluye quimioterapia como melfalán y prednisona.
This document summarizes information about immunotherapy for non-small cell lung cancer (NSCLC). It provides data on key clinical trials that evaluated immunotherapy drugs like nivolumab and pembrolizumab in previously treated NSCLC. It shows the efficacy results including overall survival benefits from these trials compared to chemotherapy. Long-term survival outcomes are also presented from pooled analyses of nivolumab trials with over 3 years of follow-up data.
Immunotherapy maintenence for advanced urothelial cancerChandan K Das
- JAVELIN Bladder 100 was a phase 3 trial investigating avelumab maintenance therapy after platinum-based chemotherapy in patients with advanced urothelial carcinoma.
- The trial found avelumab maintenance significantly improved overall survival compared to best supportive care alone, with a 31% reduction in risk of death. Progression-free survival was also significantly improved.
- Subgroup analyses found overall survival benefits were consistent across all patient subgroups, including those with PD-L1-negative tumors. Response rates were also higher with avelumab maintenance.
- The safety profile of avelumab was manageable, with most treatment-related adverse events being grade 1-2 in severity and no new safety signals
Prof. Eric Van Cutsem, MD, PhD, Neil H. Segal, MD, PhD, and Manish A. Shah, MD, discuss immunotherapy in GI cancers in this CME activity titled "The Advent of Immunotherapy in Gastrointestinal Cancers: MasterClass and Practicum on Checkpoint Inhibition and Biomarkers in Colorectal and Gastric Tumors." For the full presentation, downloadable practice aids, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2M8PcMs. CME credit will be available until July 2, 2019.
T cells genetically engineered to express chimeric antigen receptors (CAR) have proven an impressive therapeutic activity in patients with certain subtypes of B cell leukaemia or lymphoma, with promising efficacy also demonstrated in patients with multiple myeloma. However, in patients with solid tumors, objective responses to CAR-T cell therapy remain sporadic and transient. Key challenges relating to CAR T cells include the lack of tumor exclusive target, restricted CAR-T cell trafficking to tumor sites, antigen escape and heterogeneity as well as a highly immunosuppressive microenvironment. In this report, we review the current state of the CAR-T technologies as a clinical treatment in solid tumor and we highlight the preclinical innovative designs of novel CAR T cell products that are being developed to increase and expand the clinical benefits of these treatments in patients with solid malignancies.
Pathology and Oncology Expert Perspectives in the Management of Triple-Negati...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck, presented by Dr. Ira Bleiweiss, Chief of Breast Pathology at the University of Pennsylvania, and Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, will feature expert pathology and oncology perspectives on the management of triple-negative breast cancer (TNBC), including case explorations and insights into frequently asked questions. Register today to hear these expert perspectives!
Statement of Need
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack of hormone and receptor targets, therapeutic options are limited, and prognostication and treatment selection are complicated by the heterogeneity of the disease (Yang et al, 2022). In this live webinar, Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Dr. Ira Bleiweiss, Chief of Breast Pathology at the Hospital of the University of Pennsylvania, will provide expert oncology and pathology perspectives on evidence-based strategies for diagnosis, treatment, and adverse event management for patients with TNBC.
TARGET AUDIENCE
Medical oncologists, surgical oncologists, radiation oncologists, pathologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with triple-negative breast cancer (TNBC).
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
Evaluate receptor and expression status for prognostication and treatment selection in TNBC
Differentiate the pathological characteristics of the various types of TNBC
Select optimal therapy for TNBC based on shared goals, biomarker testing, and clinical data on novel therapies
Discuss strategies for timely recognition and mitigation of adverse events associated with novel TNBC therapies
El documento describe la leucemia promielocítica aguda (LPA), un subtipo de leucemia mieloide aguda. La LPA se caracteriza por la translocación cromosómica recíproca t(15;17) que fusiona los genes PML y RARA, dando lugar a la proteína de fusión PML-RARA. Esta proteína bloquea la maduración de los promielocitos y causa la leucemia. El tratamiento con ácido retinoico logra la diferenciación de los promielocitos y produce una remisión en el
El documento describe los métodos de diagnóstico de laboratorio para el cáncer, incluyendo histopatología, citología, inmunohistoquímica, diagnóstico molecular y citometría de flujo. Estos métodos permiten caracterizar las neoplasias, clasificar tumores, determinar el origen de las metástasis, evaluar marcadores pronósticos y realizar detección de enfermedad mínima residual. El diagnóstico molecular incluye análisis citogenéticos, detección de mutaciones y perfiles de expresión g
Cancer immunotherapy harnesses the power of the immune system to fight cancer. Various immunotherapy approaches have been developed including vaccines, cytokines, monoclonal antibodies, and engineered T cells. Many immunotherapies have received FDA approval based on clinical trials demonstrating improved outcomes for cancer patients. New clinical trial designs are exploring immunotherapy combinations in "basket trials" that group patients by biomarkers rather than cancer type and "umbrella trials" that test multiple therapies in one study. Immunotherapy is transforming cancer treatment by activating the immune system against tumors.
El documento describe la anatomía y fisiología de la glándula mamaria, así como los tipos y tratamientos más comunes de cáncer de mama. Explica que la glándula mamaria consta de aproximadamente 20 lóbulos con conductos galactóforos que drenan al pezón, y que emite una prolongación que rodea el borde del músculo pectoral mayor. También describe factores de riesgo para el cáncer de mama como la edad y antecedentes familiares, así como los síntomas, exámenes de diagnó
TEST DE ACTIVACION BASOFILO en alergia.pptxEDGAR MATOS
BAT se ha convertido en una Herramienta ampliamente utilizada de actividad alérgica.
Comparado con la determinación de IgE en suero.
BAT refleja una Respuesta Funcional
El documento clasifica y describe diferentes tipos de tumores cutáneos. Explica que los tumores se dividen en benignos y malignos. Los benignos incluyen nevos, queratosis, papilomas, hemangiomas y lipomas. Los malignos incluyen melanoma y carcinomas, siendo el melanoma el más peligroso debido a su alta tasa de metástasis a otros órganos. El documento se enfoca en describir las características clínicas, factores de riesgo, clasificaciones, pronóstico y tratamiento del melanoma cutáneo.
Este documento proporciona información sobre el cáncer de mama, incluyendo su definición, tipos, factores de riesgo, síntomas, diagnóstico, estadificación y opciones de tratamiento y detección temprana. Explica que el cáncer de mama se origina en las células de los conductos o lóbulos de la mama y que los tipos más comunes son el ductal y el lobular. También describe los factores que aumentan el riesgo como la edad, antecedentes familiares y cambios hormonales,
Este documento resume la evolución del tratamiento del cáncer rectal, desde la cirugía como único tratamiento hasta la incorporación de la radioterapia y quimioterapia adyuvante o neoadyuvante. Estudios clave mostraron que la radioterapia preoperatoria reduce la tasa de recidivas locales y mejora los resultados quirúrgicos. Más recientemente, ensayos añadieron quimioterapia neoadyuvante con esquemas como FOLFOX, mostrando mayores tasas de downstaging tumoral y supervivencia, con
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)bkling
On May 22, 2013, SHARE presented "Recurrent Ovarian Cancer: Now What?" The program featured Dr. Ginger Gardner and Dr. Paul Sabbatini of Memorial Sloan-Kettering Cancer Center discussing treatment strategies, as well as new approaches and agents, for managing an ovarian cancer recurrence. Listen to the audio here http://www.sharecancersupport.org/sabbatini.
The information in this presentation is not intended to be a substitute for professional medical advice, diagnosis or treatment.
Este documento describe el carcinoma gástrico. Presenta variaciones geográficas en su incidencia, siendo común en Japón y partes de Europa y Asia. Describe la morfología, clasificación de Lauren, diferencias entre cáncer gástrico temprano y avanzado, patrones macroscópicos, subtipos histológicos, síntomas clínicos y formas de extensión de la enfermedad.
Este documento describe la clasificación molecular del cáncer de mama, dividiéndolo en subtipos basados en la expresión de biomarcadores como los receptores de estrógeno y HER2. Estos subtipos, como luminal A, luminal B, HER2-positivo y basal, tienen diferentes pronósticos y respuestas a tratamientos. La clasificación molecular proporciona información más precisa que la histopatológica tradicional para guiar las terapias y predecir resultados.
Este documento describe la anatomía, fisiología y patología de la glándula mamaria. Describe la anatomía de la mama y sus componentes como el pezón y la areola. Explica los sistemas linfáticos y vascularización de la mama. Luego, define el cáncer de mama y discute factores de riesgo, tipos, clasificación, características y pronóstico. Finalmente, describe los subtipos histológicos del carcinoma ductal in situ y sus patrones de crecimiento.
FIRE 3 Trail FOLFIRI+Cetuximab Vs FOLFIRI+BevacizumabAhmed Allam
This randomized, open-label, phase 3 trial compared FOLFIRI plus cetuximab (C+F) versus FOLFIRI plus bevacizumab (B+F) as first-line treatment for KRAS wild-type metastatic colorectal cancer. The trial found that C+F resulted in improved progression-free survival and overall survival compared to B+F. C+F was associated with increased rates of acneiform rash, paronychia, and hypomagnesemia but similar rates of other adverse events compared to B+F. The trial demonstrated that for patients with KRAS wild-type mCRC, first-line treatment with C+F provided superior
Community Oncology Clinical Debates: Advanced Melanoma
Downloadable slide decks are a great tool for self study and teaching purposes. They are non-certified resources available to enhance your knowledge.
Review a downloadable slide deck by Antoni Ribas, MD, PhD, covering the most clinically relevant new data reported from Community Oncology Clinical Debates: Advanced Melanoma.
Target Audience
This educational activity has been designed to meet the unique learning needs of oncologists involved in the treatment of patients with advanced melanoma.
Disclaimer
This slide deck in its original and unaltered format is for educational purposes and is current as of June 2012. All materials contained herein reflect the views of the faculty, and not those of IMER, the CME provider, or the commercial supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should not rely on this information as a substitute for professional medical advice, diagnosis, or treatment. The use of any information provided is solely at your own risk,
and readers should verify the prescribing information and all data before treating patients or employing any therapeutic products described in this educational activity.
Dana-Farber dermatologist Jennifer Lin, MD, discusses the latest research and treatment for melanoma.
This presentation was originally given as part of Dana-Farber's Tuesday Talks speaker series. In this talk, Lin provides an overview of melanoma, including recent research, progress and future goals.
Immunotherapy maintenence for advanced urothelial cancerChandan K Das
- JAVELIN Bladder 100 was a phase 3 trial investigating avelumab maintenance therapy after platinum-based chemotherapy in patients with advanced urothelial carcinoma.
- The trial found avelumab maintenance significantly improved overall survival compared to best supportive care alone, with a 31% reduction in risk of death. Progression-free survival was also significantly improved.
- Subgroup analyses found overall survival benefits were consistent across all patient subgroups, including those with PD-L1-negative tumors. Response rates were also higher with avelumab maintenance.
- The safety profile of avelumab was manageable, with most treatment-related adverse events being grade 1-2 in severity and no new safety signals
Prof. Eric Van Cutsem, MD, PhD, Neil H. Segal, MD, PhD, and Manish A. Shah, MD, discuss immunotherapy in GI cancers in this CME activity titled "The Advent of Immunotherapy in Gastrointestinal Cancers: MasterClass and Practicum on Checkpoint Inhibition and Biomarkers in Colorectal and Gastric Tumors." For the full presentation, downloadable practice aids, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2M8PcMs. CME credit will be available until July 2, 2019.
T cells genetically engineered to express chimeric antigen receptors (CAR) have proven an impressive therapeutic activity in patients with certain subtypes of B cell leukaemia or lymphoma, with promising efficacy also demonstrated in patients with multiple myeloma. However, in patients with solid tumors, objective responses to CAR-T cell therapy remain sporadic and transient. Key challenges relating to CAR T cells include the lack of tumor exclusive target, restricted CAR-T cell trafficking to tumor sites, antigen escape and heterogeneity as well as a highly immunosuppressive microenvironment. In this report, we review the current state of the CAR-T technologies as a clinical treatment in solid tumor and we highlight the preclinical innovative designs of novel CAR T cell products that are being developed to increase and expand the clinical benefits of these treatments in patients with solid malignancies.
Pathology and Oncology Expert Perspectives in the Management of Triple-Negati...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck, presented by Dr. Ira Bleiweiss, Chief of Breast Pathology at the University of Pennsylvania, and Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, will feature expert pathology and oncology perspectives on the management of triple-negative breast cancer (TNBC), including case explorations and insights into frequently asked questions. Register today to hear these expert perspectives!
Statement of Need
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes of invasive breast cancer, TNBC has high rates of metastasis and a poor prognosis. Due to the lack of hormone and receptor targets, therapeutic options are limited, and prognostication and treatment selection are complicated by the heterogeneity of the disease (Yang et al, 2022). In this live webinar, Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Dr. Ira Bleiweiss, Chief of Breast Pathology at the Hospital of the University of Pennsylvania, will provide expert oncology and pathology perspectives on evidence-based strategies for diagnosis, treatment, and adverse event management for patients with TNBC.
TARGET AUDIENCE
Medical oncologists, surgical oncologists, radiation oncologists, pathologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with triple-negative breast cancer (TNBC).
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
Evaluate receptor and expression status for prognostication and treatment selection in TNBC
Differentiate the pathological characteristics of the various types of TNBC
Select optimal therapy for TNBC based on shared goals, biomarker testing, and clinical data on novel therapies
Discuss strategies for timely recognition and mitigation of adverse events associated with novel TNBC therapies
El documento describe la leucemia promielocítica aguda (LPA), un subtipo de leucemia mieloide aguda. La LPA se caracteriza por la translocación cromosómica recíproca t(15;17) que fusiona los genes PML y RARA, dando lugar a la proteína de fusión PML-RARA. Esta proteína bloquea la maduración de los promielocitos y causa la leucemia. El tratamiento con ácido retinoico logra la diferenciación de los promielocitos y produce una remisión en el
El documento describe los métodos de diagnóstico de laboratorio para el cáncer, incluyendo histopatología, citología, inmunohistoquímica, diagnóstico molecular y citometría de flujo. Estos métodos permiten caracterizar las neoplasias, clasificar tumores, determinar el origen de las metástasis, evaluar marcadores pronósticos y realizar detección de enfermedad mínima residual. El diagnóstico molecular incluye análisis citogenéticos, detección de mutaciones y perfiles de expresión g
Cancer immunotherapy harnesses the power of the immune system to fight cancer. Various immunotherapy approaches have been developed including vaccines, cytokines, monoclonal antibodies, and engineered T cells. Many immunotherapies have received FDA approval based on clinical trials demonstrating improved outcomes for cancer patients. New clinical trial designs are exploring immunotherapy combinations in "basket trials" that group patients by biomarkers rather than cancer type and "umbrella trials" that test multiple therapies in one study. Immunotherapy is transforming cancer treatment by activating the immune system against tumors.
El documento describe la anatomía y fisiología de la glándula mamaria, así como los tipos y tratamientos más comunes de cáncer de mama. Explica que la glándula mamaria consta de aproximadamente 20 lóbulos con conductos galactóforos que drenan al pezón, y que emite una prolongación que rodea el borde del músculo pectoral mayor. También describe factores de riesgo para el cáncer de mama como la edad y antecedentes familiares, así como los síntomas, exámenes de diagnó
TEST DE ACTIVACION BASOFILO en alergia.pptxEDGAR MATOS
BAT se ha convertido en una Herramienta ampliamente utilizada de actividad alérgica.
Comparado con la determinación de IgE en suero.
BAT refleja una Respuesta Funcional
El documento clasifica y describe diferentes tipos de tumores cutáneos. Explica que los tumores se dividen en benignos y malignos. Los benignos incluyen nevos, queratosis, papilomas, hemangiomas y lipomas. Los malignos incluyen melanoma y carcinomas, siendo el melanoma el más peligroso debido a su alta tasa de metástasis a otros órganos. El documento se enfoca en describir las características clínicas, factores de riesgo, clasificaciones, pronóstico y tratamiento del melanoma cutáneo.
Este documento proporciona información sobre el cáncer de mama, incluyendo su definición, tipos, factores de riesgo, síntomas, diagnóstico, estadificación y opciones de tratamiento y detección temprana. Explica que el cáncer de mama se origina en las células de los conductos o lóbulos de la mama y que los tipos más comunes son el ductal y el lobular. También describe los factores que aumentan el riesgo como la edad, antecedentes familiares y cambios hormonales,
Este documento resume la evolución del tratamiento del cáncer rectal, desde la cirugía como único tratamiento hasta la incorporación de la radioterapia y quimioterapia adyuvante o neoadyuvante. Estudios clave mostraron que la radioterapia preoperatoria reduce la tasa de recidivas locales y mejora los resultados quirúrgicos. Más recientemente, ensayos añadieron quimioterapia neoadyuvante con esquemas como FOLFOX, mostrando mayores tasas de downstaging tumoral y supervivencia, con
Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)bkling
On May 22, 2013, SHARE presented "Recurrent Ovarian Cancer: Now What?" The program featured Dr. Ginger Gardner and Dr. Paul Sabbatini of Memorial Sloan-Kettering Cancer Center discussing treatment strategies, as well as new approaches and agents, for managing an ovarian cancer recurrence. Listen to the audio here http://www.sharecancersupport.org/sabbatini.
The information in this presentation is not intended to be a substitute for professional medical advice, diagnosis or treatment.
Este documento describe el carcinoma gástrico. Presenta variaciones geográficas en su incidencia, siendo común en Japón y partes de Europa y Asia. Describe la morfología, clasificación de Lauren, diferencias entre cáncer gástrico temprano y avanzado, patrones macroscópicos, subtipos histológicos, síntomas clínicos y formas de extensión de la enfermedad.
Este documento describe la clasificación molecular del cáncer de mama, dividiéndolo en subtipos basados en la expresión de biomarcadores como los receptores de estrógeno y HER2. Estos subtipos, como luminal A, luminal B, HER2-positivo y basal, tienen diferentes pronósticos y respuestas a tratamientos. La clasificación molecular proporciona información más precisa que la histopatológica tradicional para guiar las terapias y predecir resultados.
Este documento describe la anatomía, fisiología y patología de la glándula mamaria. Describe la anatomía de la mama y sus componentes como el pezón y la areola. Explica los sistemas linfáticos y vascularización de la mama. Luego, define el cáncer de mama y discute factores de riesgo, tipos, clasificación, características y pronóstico. Finalmente, describe los subtipos histológicos del carcinoma ductal in situ y sus patrones de crecimiento.
FIRE 3 Trail FOLFIRI+Cetuximab Vs FOLFIRI+BevacizumabAhmed Allam
This randomized, open-label, phase 3 trial compared FOLFIRI plus cetuximab (C+F) versus FOLFIRI plus bevacizumab (B+F) as first-line treatment for KRAS wild-type metastatic colorectal cancer. The trial found that C+F resulted in improved progression-free survival and overall survival compared to B+F. C+F was associated with increased rates of acneiform rash, paronychia, and hypomagnesemia but similar rates of other adverse events compared to B+F. The trial demonstrated that for patients with KRAS wild-type mCRC, first-line treatment with C+F provided superior
Community Oncology Clinical Debates: Advanced Melanoma
Downloadable slide decks are a great tool for self study and teaching purposes. They are non-certified resources available to enhance your knowledge.
Review a downloadable slide deck by Antoni Ribas, MD, PhD, covering the most clinically relevant new data reported from Community Oncology Clinical Debates: Advanced Melanoma.
Target Audience
This educational activity has been designed to meet the unique learning needs of oncologists involved in the treatment of patients with advanced melanoma.
Disclaimer
This slide deck in its original and unaltered format is for educational purposes and is current as of June 2012. All materials contained herein reflect the views of the faculty, and not those of IMER, the CME provider, or the commercial supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should not rely on this information as a substitute for professional medical advice, diagnosis, or treatment. The use of any information provided is solely at your own risk,
and readers should verify the prescribing information and all data before treating patients or employing any therapeutic products described in this educational activity.
Dana-Farber dermatologist Jennifer Lin, MD, discusses the latest research and treatment for melanoma.
This presentation was originally given as part of Dana-Farber's Tuesday Talks speaker series. In this talk, Lin provides an overview of melanoma, including recent research, progress and future goals.
123,590 new cases of melanoma were reported in the US last year. The risk of death from melanoma increases with age, with 41.5% of cases occurring in those aged 65 and over, and only 0.7% in those under 19. Stage also impacts survival rates, with 90% surviving stage 1 melanoma but only 5% surviving stage 4 melanoma where it has spread to other organs like the brain.
This document summarizes genetic markers and targeted therapies for melanoma. It notes that BRAF mutations are present in 40-70% of melanomas and that drugs like vemurafenib and dabrafenib that target mutated BRAF have shown improved survival compared to chemotherapy in clinical trials. For melanomas with NRAS or KIT mutations, drugs targeting the MEK pathway or KIT, respectively, are under investigation. The document also reviews genetic markers and potential targeted therapies for different anatomical sites of melanoma like the skin, mucosa, and uveal melanoma.
This document summarizes systemic treatment options for uveal melanoma including FDA-approved drugs and clinical trials. It discusses interferon alpha and pegylated interferon alpha as adjuvant therapies approved in the 1990s. It also discusses targeted therapies like vemurafenib approved in 2011 for BRAF V600E mutant melanomas, and immunotherapies like ipilimumab approved in 2011. Ongoing clinical trials exploring therapies targeting GNAQ/GNA11 mutations in uveal melanoma are summarized.
Immune checkpoint inhibitors work by releasing brakes on the immune system called checkpoints that normally limit anti-tumor immune responses. In clinical trials, checkpoint inhibitors have demonstrated the ability to induce long-lasting responses in a subset of patients with various cancers including melanoma. Combining checkpoint inhibitors with other immunotherapies, targeted therapies, or cell-based therapies may help generate anti-tumor immune responses in patients whose tumors do not respond to checkpoint inhibitors alone. Managing cancer in the era of checkpoint inhibitors will likely involve complex combinations of different treatment approaches.
This document discusses retinopathy observed in some patients participating in clinical trials of MEK inhibitors for metastatic melanoma. Optical coherence tomography revealed neuroretinal elevations in affected patients. Central retinal thickness increased in a dose-dependent manner after treatment but then decreased despite continued treatment, corresponding with resolution of mild and short-lived visual symptoms. Treatment with the MEK inhibitor binimetinib commonly induced transient retinopathy but visual function was usually not seriously impaired.
This document summarizes endocrine morbidities that can result from cancer therapy involving radiation or chemotherapy. It discusses how the hypothalamic-pituitary axis, thyroid, parathyroids, gonads, and other endocrine glands can be affected. Specific risks include growth hormone deficiency, precocious puberty, hypothyroidism, thyroid cancer, ovarian dysfunction, and testicular damage leading to infertility. The risks depend on factors like treatment dose, age at treatment, and time since treatment. Regular screening is important to monitor for effects, and hormone replacement therapy may be needed. Protecting gonadal function through semen/oocyte cryopreservation is also discussed.
Small molecule inhibitors of PI4 KinaseDavid Andrews
Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- and β- and their effects on phosphatidylinositol signalling. The importance of small molecule probes to help us understand cellular pathways in cancer
Dasatinib is a second-generation BCR-ABL tyrosine kinase inhibitor that is more potent than imatinib and effective against some imatinib-resistant mutations. Unlike imatinib, dasatinib interferes with platelet function by targeting Src family kinases, which may contribute to increased bleeding risk in patients. Clinical trials found dasatinib achieved high rates of cytogenetic and molecular response in chronic myeloid leukemia patients, including those resistant to or intolerant of imatinib. However, dasatinib treatment also carried risks of myelosuppression and bleeding that required dose reductions in some cases.
Webinar: Discovering Small Molecule Protein-Protein Interaction Inhibitors th...Dr. Wolfgang Kissel
This document advertises a webinar from Computist Bio-Nanotech about designing small molecule protein-protein interaction inhibitors through computational design. The webinar will discuss using computational methods to discover drug compounds that target disease proteins, with examples of designing inhibitors for the Ras/Raf interaction. Computational design could accelerate drug discovery by designing molecules with known modes of action, improving compounds, and making previously difficult targets feasible to drug.
This document summarizes the results of a clinical trial investigating the efficacy and safety of pembrolizumab (anti-PD-1 antibody) in patients with advanced melanoma that progressed after treatment with ipilimumab. The overall response rate was 26% in the 2 mg/kg group and 10% in the 10 mg/kg group, with responses ongoing after 1 year. Pembrolizumab demonstrated a manageable safety profile, with grade 3-4 drug-related adverse events occurring in 12% of patients. This trial provides evidence that pembrolizumab is an effective treatment option for patients with advanced melanoma who have progressed on ipilimumab.
Dr. Patrick Hwu presents the latest information on immunotherapies for melanoma at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
This document summarizes recent advances in pancreatic cancer. It covers molecular genetics and tumor biology, methods for early detection of precursor lesions, investigation modalities like imaging tests and tumor markers, surgical management approaches including criteria for resectability, and adjuvant treatment modalities like chemotherapy and radiation. Newer chemotherapy regimens have improved survival rates and some targeted therapies show promise. Multidisciplinary treatment at high-volume centers results in better outcomes. While improvements have been made, pancreatic cancer remains difficult to treat and more research is still needed.
This document summarizes recent advances in the treatment of metastatic colorectal cancer (mCRC), focusing on the addition of targeted therapies like bevacizumab, cetuximab, and panitumumab to chemotherapy regimens. Key findings include improved progression-free and overall survival when these biologics are added to first-line therapies like FOLFOX or FOLFIRI for mCRC. However, the benefits of EGFR inhibitors appear limited to patients with KRAS wild-type tumors, while the benefits of bevacizumab seem independent of KRAS mutation status. Ongoing studies continue exploring biomarkers like KRAS to help personalize first-line mCRC treatment.
Dr. Natasha Tiffany has nearly a decade of experience treating cancer patients with targeted therapies as a physician at Hematology Oncology of Salem. Targeted therapy utilizes either antibody drugs that mimic immune system proteins targeting cancer cells or smaller molecule drugs, and has become a major resource in cancer treatment. Some examples of targeted therapy drugs include Gleevec, which is used to treat gastrointestinal stromal tumors and certain leukemias, Iressa for non-small-cell lung cancer with epidermal growth factor receptor mutations, and Sutent and Velcade for kidney cancer and multiple myeloma respectively.
This document provides an overview of principles of systemic therapy in cancer, including chemotherapy, endocrine therapy, immunotherapy, and targeted therapy. It discusses various classes of chemotherapeutic agents and their mechanisms of action, administration methods, principles of combination chemotherapy, and parameters for evaluating treatment responses and toxicities. It also summarizes several hormonal agents used in endocrine therapy for cancers like breast and prostate cancer. Immunotherapies and targeted therapies discussed include monoclonal antibodies, tyrosine kinase inhibitors, and other small molecule inhibitors used to treat various cancers.
1) The document discusses PARP inhibition in breast cancer, from preclinical rationale to clinical trials. It summarizes key trials like OlympiAD and EMBRACA which showed improved progression-free survival with PARP inhibitors olaparib and talazoparib in advanced BRCA-mutated breast cancer.
2) It also discusses the OlympiA trial, which is evaluating olaparib as adjuvant therapy in early-stage high-risk BRCA-mutated breast cancer patients to reduce the risk of disease recurrence.
3) Finally, it briefly touches on the increased rates of BRCA testing post the "Angelina Jolie effect" and the need to expand BRCA testing
Dr. Michael Davies presents the latest information on targeted melanoma therapies at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
Update on Management of Triple Negative Breast Cancerspa718
This document provides an update on the management of triple negative breast cancer from Dr. Banu Arun at MD Anderson Cancer Center. It discusses that triple negative breast cancer is a heterogeneous disease comprised of several molecular subtypes with different characteristics and potential treatment targets. Clinical trials exploring chemotherapy regimens, platinum agents, PARP inhibitors, anti-angiogenic drugs, and immunotherapies are summarized. Ongoing research aims to better define the subtypes in order to personalize treatment for triple negative breast cancer patients.
This document summarizes information on the treatment of metastatic colorectal cancer (mCRC) presented by Dr. Mohamed Abdulla at the Amgen Symposium in Asyut, Egypt on February 20, 2018. It discusses trends in the incidence and mortality of colon cancer in Egypt over time. It also reviews the evolution of systemic therapies for mCRC since the 1980s, highlighting improvements in overall survival associated with various chemotherapy regimens and targeted agents. Finally, it discusses factors important for determining optimal treatment sequences, including the use of predictive biomarkers, tumor location, and induction of tumor shrinkage.
1) The document discusses treatment strategies for metastatic colorectal cancer (mCRC), including the importance of multidisciplinary teams, sequencing of chemotherapy and targeted therapies, and continuing treatment beyond progression.
2) Key points addressed include using oxaliplatin or irinotecan as the chemotherapy backbone, adding targeted therapies like bevacizumab or anti-EGFR antibodies based on molecular markers, and exploring more intensive strategies like FOLFOXIRI for certain patients.
3) Maintaining quality of life across all treatment lines is emphasized as the overarching goal.
New Data on Resistance to DAAs and Implications for Therapy.2015hivlifeinfo
This document provides an overview of a presentation on new data regarding resistance to direct-acting antivirals (DAAs) and implications for HCV therapy. It includes the faculty list and their disclosures, as well as slides summarizing recent studies on DAA resistance variants, their impact on treatment outcomes, and persistence after treatment failure. Key findings discussed are the role of NS3 Q80K testing prior to simeprevir + sofosbuvir in genotype 1a patients, effectiveness of DAA regimens against prior protease inhibitor resistance, and durability of NS5A resistance variants.
This document discusses anti-angiogenic therapy in colorectal cancer. It begins with defining cancer and explaining the cell cycle and angiogenesis. It then summarizes several phase 3 trials that evaluated anti-angiogenic therapies in metastatic colorectal cancer, both as maintenance therapies and in patients with BRAF mutations. The document concludes by noting that angiogenesis is an appealing cancer treatment target, anti-angiogenic therapies have contributed to metastatic colorectal cancer treatment, and more work is still needed regarding biomarkers and adjuvant settings.
Colorectal Cancer Research & Treatment News - recap from the May 2014 ASCO co...Fight Colorectal Cancer
This document summarizes key findings from the PRIME trial evaluating the addition of panitumumab to FOLFOX4 as first-line treatment for metastatic colorectal cancer. Biomarker analysis found that KRAS exon 2 wild-type tumors derived greater benefit from the addition of panitumumab, with a progression-free survival advantage compared to FOLFOX4 alone. Further biomarker testing found mutations in other RAS isoforms or BRAF reduced likelihood of benefit from panitumumab. The results support use of RAS/BRAF mutation testing to select patients for first-line anti-EGFR therapy in combination with chemotherapy.
This document summarizes a presentation on the management of metastatic colorectal cancer (mCRC) in 2017. It discusses several key points:
1) Patient stratification is important in determining treatment approach for mCRC, taking into account factors like disease extent and symptoms.
2) A multidisciplinary team approach is mandatory for developing optimal treatment plans.
3) Assessment of predictive biomarkers like RAS mutations helps determine which first-line treatments may be most effective.
4) Tumor location (right vs left-sided colon cancer) can impact treatment outcomes and response to certain drugs like anti-EGFR therapies.
5) Multiple clinical trials over time have led to improved survival outcomes and more
This document discusses approaches to angiogenesis and predictive biomarkers for anti-angiogenic therapies. It summarizes that:
1) Angiogenesis is driven by VEGF and its receptors, and agents targeting this pathway like bevacizumab have shown efficacy in some cancers;
2) No predictive biomarker for anti-angiogenic response has been validated, but candidates include HER2 positivity in breast cancer and multi-omics approaches to identify VEGF-driven tumors;
3) Future progress may require more selective patient populations that are likely to respond to anti-angiogenic therapies based on their tumor and host biology.
Richard Carvajal, MD presents Targeted Therapy for Uveal Melanoma and the Uveal Melanoma Clinical Research Landscape at the 2017 CURE OM Patient & Caregiver Symposium.
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoMauricio Lema
Ponencia en el VII Congreso internacional de coloproctología, Bogotá, 18.08.2016. Con énfasis en los estudios recientes en terapia antiangiogénica, y el impacto del lado del primario en el pronóstico (y aspectos predictivos) de la enfermedad metastásica.
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014Hivlife Info
Marc Bourlière, MD and Graham R. Foster, FRCP, PhD presented on managing cirrhotic HCV patients. They discussed which cirrhotic patients should be treated, how to treat them, and ensuring informed decision making. Patients with Child-Pugh A cirrhosis should be strongly advised to undergo therapy, while more advanced cases require careful consideration. New direct-acting antiviral regimens have increased sustained virologic response rates in cirrhotic patients, but they still face higher risks of side effects and disease progression if treatment is delayed. Physicians must fully inform patients of risks from both immediate treatment and deferring treatment to facilitate shared decision making.
Managing cirrhotic HCV patients. Whom to treat, how to treat.2014hivlifeinfo
Cirrhotic patients are the most in need of HCV treatment but also face challenges. Treatment is recommended for Child-Pugh A patients but more advanced cirrhosis requires caution. New drug combinations with direct-acting antivirals and pegylated interferon/ribavirin have increased sustained virologic response rates in cirrhotic patients, though they remain at risk for side effects and worsening liver function. Careful monitoring is needed when treating cirrhotic patients, especially those with significant risk factors like low platelet count or albumin level. Promising interferon-free regimens show high response rates even in prior treatment failures and may improve options for cirrhotic patients.
Expanding treatment platform in m crc bayer - asyut 2018Mohamed Abdulla
Describes the different therapeutic approach to patients with metastatic colorectal cancer in the 3rd subsequent treatment line with especial emphasis on the role of regorafenib and how to manipulate the adverse events while not compromise the outcome.
This document summarizes key information about ovarian cancer, including epidemiology, staging, treatment milestones, prognostic factors, and recent clinical trials. It notes that the median age of diagnosis is 63 years and discusses improvements in 5-year survival over time. New developments discussed include the role of surgery, chemotherapy regimens, targeted therapies like bevacizumab, and trials in recurrent settings.
El futuro del tratamiento del cáncer renal metastásico: inmunoterapia y terap...Mauricio Lema
Ponencia en el primer simposio de la Asociación Colombiana de Hematología y Oncología (ACHO) de cáncer genitourinario, Bogotá, septiembre 23 y 24 de 2016.
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
Giloy in Ayurveda - Classical Categorization and SynonymsPlanet Ayurveda
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
PGx Analysis in VarSeq: A User’s PerspectiveGolden Helix
Since our release of the PGx capabilities in VarSeq, we’ve had a few months to gather some insights from various use cases. Some users approach PGx workflows by means of array genotyping or what seems to be a growing trend of adding the star allele calling to the existing NGS pipeline for whole genome data. Luckily, both approaches are supported with the VarSeq software platform. The genotyping method being used will also dictate what the scope of the tertiary analysis will be. For example, are your PGx reports a standalone pipeline or would your lab’s goal be to handle a dual-purpose workflow and report on PGx + Diagnostic findings.
The purpose of this webcast is to:
Discuss and demonstrate the approaches with array and NGS genotyping methods for star allele calling to prep for downstream analysis.
Following genotyping, explore alternative tertiary workflow concepts in VarSeq to handle PGx reporting.
Moreover, we will include insights users will need to consider when validating their PGx workflow for all possible star alleles and options you have for automating your PGx analysis for large number of samples. Please join us for a session dedicated to the application of star allele genotyping and subsequent PGx workflows in our VarSeq software.
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Know the difference between Endodontics and Orthodontics.Gokuldas Hospital
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
How to Control Your Asthma Tips by gokuldas hospital.Gokuldas Hospital
Respiratory issues like asthma are the most sensitive issue that is affecting millions worldwide. It hampers the daily activities leaving the body tired and breathless.
The key to a good grip on asthma is proper knowledge and management strategies. Understanding the patient-specific symptoms and carving out an effective treatment likewise is the best way to keep asthma under control.
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort.
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
1. Targeted Therapy for BRAF V600–
Mutant Melanoma
This program is supported by educational grants from
in association with
2. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
About These Slides
Users are encouraged to use these slides in their own
noncommercial presentations, but we ask that content
and attribution not be changed. Users are asked to honor
this intent
These slides may not be published or posted online
without permission from Clinical Care Options
(email permissions@clinicaloptions.com)
Disclaimer
The materials published on the Clinical Care Options Web site reflect the views of the authors of the
CCO material, not those of Clinical Care Options, LLC, the CME providers, or the companies providing
educational grants. The materials may discuss uses and dosages for therapeutic products that have not
been approved by the United States Food and Drug Administration. A qualified healthcare professional
should be consulted before using any therapeutic product discussed. Readers should verify all information
and data before treating patients or using any therapies described in these materials.
3. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Faculty
Keith T. Flaherty, MD
Director of Temeer Center for Targeted Therapy
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Keith T. Flaherty, MD has disclosed that he has received
consulting fees from GlaxoSmithKline, Novartis, and
Roche/Genentech.
4. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Incidence of Key Driver Oncogenes in
Melanoma
BRAF ~ 50%
NRAS ~ 20%
CKIT ~ 1%
– Primarily mucosal and acral lentiginous
GNAQ/GNA11 ~ 1%
– Almost exclusively uveal
Nikolaou VA, et al. J Invest Dermatol. 2012;132:854-863.
Smalley KS, et al. Semin Oncol. 2012;39:204-214.
5. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
BRAF Mutations: Biology and Practice
BRAF mutations
Stable across primary to metastatic
melanoma
Detectable in formalin-fixed,
paraffin-embedded tumor samples
BRAF Mutation, % N = 677
All BRAF mutations 47
V600E 72
V600K 23
V600R/L 4
Non-V600 2
Jakob J, et al. ASCO 2011. Abstract 8500.
NRAS
CRAFBRAF
MEK
ERK
6. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
BRAF Mutation Testing
BRAF mutations are present throughout melanoma
disease progression
– If metastasis biopsy not available, most recent melanoma
surgery sample adequate (eg, lymph node)
BRAF mutation testing is commercially available
– FDA-approved tests
– Cobas 4800 BRAF V600 Mutation Test (vemurafenib)
– THxID BRAF Kit (dabrafenib with or without trametinib)
NCCN. Clinical practice guidelines in oncology: melanoma. v.1.2014.
7. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
BRAF “Inhibitors” Only Inhibit in the
Context of BRAF Mutation
CRAFBRAF
MEK
ERK
P
P
CRAF
MEK
ERK
P
P
CRAF
Heidorn SJ, et al. Cell. 2010;140:209-221. Poulikakos PI, et al. Nature. 2010; 464:427-430.
Hatzivassiliou G, et al. Nature. 2010;464:431-435.
RAS-GTP
9. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Key Target Selectivity of Raf Inhibitors
Target Kinase IC50 (nM)
Vemurafenib Dabrafenib
BRAF-V600E 31 0.6
CRAF 48 5
BRAF 100 12
Bollag G, et al. Nature. 2010;467:596-599. Kefford R, et al. ASCO 2010. Abstract 8503.
10. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Sosman J, et al. N Engl J Med. 2012;366:707-714.
Tumor regression: ~ 90% of patients
8 confirmed CRs
BRIM-2 Phase II Study of Vemurafenib in
Metastatic Melanoma: Tumor Regression
60
40
20
0
-20
-40
-60
-80
-100
PercentChangeFromBaselinein
LongestDiameterofTargetLesion
Patients Treated With Vemurafenib
Disease Stage
M1a
M1b
M1c
11. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
1. Chapman PB, et al. N Engl J Med. 2011;364:2507-2516. 2. McArthur G, et al. ECCO-ESMO 2011.
Abstract LBA28. 3. Hauschild A, et al. Lancet. 2012;380:358-365. 4. Robert C, et al. ASCO 2012.
Abstract LBA8509. 5. Flaherty KT, et al. N Engl J Med. 2012;367:107-114.
Phase III Trials in BRAF V600E–Mutant
Melanoma
Trial Name NCT Identifier N Treatment Arms
BRIM-3[1,2]
NCT01006980 675 Vemurafenib 960 mg PO BID (n = 337)
Dacarbazine 1000 mg/m2
IV q3w
(n = 338)
BRF113683[3]
NCT01227889 250 Dabrafenib 150 mg PO BID (n = 187)
Dacarbazine 1000 mg/m2
IV q3w (n = 63)
METRIC[4,5]
NCT01245062 322 Trametinib 2 mg PO QD (n = 214)
Dacarbazine1000 mg/m2
IV q3w or
paclitaxel 175 mg/m2
q3w (n = 108)
12. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Chapman PB, et al. N Engl J Med. 2011;364:2507-2516.
250
200
150
100
50
0
-50
-100
%ChangeFromBaselinein
DiametersofTargetLesions
Patients Treated With Vemurafenib
Unresectable
stage IIIc
M1a M1b M1c
Disease Stage 100
80
60
40
20
0
0 2 4 6 8 10 12
Mos
PFS(%)
HR: 0.26 (95% Cl: 0.20-0.33;
P < .001)
Vemurafenib (n = 275)
Dacarbazine (n = 274)
BRIM-3 Phase III Study of Vemurafenib vs
DTIC in Melanoma: Response and PFS
13. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Mos
Vemurafenib (n = 337)
Est 6-mo survival: 83%
Median follow-up: 6.2 mos
Dacarbazine (n = 338)
Est 6-mo survival: 63%
Median follow-up: 4.5 mos
OS(%)
HR: 0.44
(95% CI: 0.33-0.59)
Dacarbazine
median OS:
7.9 mos
McArthur G, et al. ECCO-ESMO 2011. Abstract LBA28.
BRIM-3 Phase III Study of Vemurafenib vs
Dacarbazine in Melanoma: OS
100
90
80
70
60
50
40
30
20
10
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
14. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Phase III Study of Dabrafenib vs DTIC in
Melanoma: Response and PFS
Hauschild A, et al. Lancet Oncol. 2012;380:358-365.
Unresectable IIC
M1A
M1B
M1C
100
80
60
40
20
0
-20
-40
-60
-80
-100
ChangeatMaximumReductionFrom
BaselineMeasurement(%)
100
90
80
70
60
50
40
30
20
10
0PFS(%)
0 1 2 3 4 5 6 7 8 9
Dabrafenib
Dacarbazine
Mos
15. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Trametinib (n = 214)
Single-Agent MEKi (Trametinib) in BRAF-
Mutant/BRAFi-Naive Metastatic Melanoma
Robert C, et al. ASCO 2012. Abstract LBA8509.
Disease Stage
39%
M1c
M1b
M1a
IIIC
Unknown
100
80
60
40
20
0
-20
-40
-60
-80
-100
%ChangeFromBaselinein
DiametersofTargetLesions
16. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Phase III METRIC: Trametinib (MEKi) vs
Dacarbazine or Paclitaxel
Flaherty KT, et al. N Engl J Med. 2012;367:107-
114.
1.0
0.8
0.6
0.4
0.2
0
0 2 4 6
8
Mos Since Randomization
ProbabilityofPFS
HR: 0.45
(95% Cl: 0.33-0.63;
P < .001)
Trametinib
(n = 214)
Chemotherapy
(n = 108)
ProbabilityofOS
1.0
0.8
0.6
0.4
0.2
0
0 2 4 6 8 10
Trametinib
(n = 214)
Chemotherapy
(n = 108)
HR: 0.54 (95% Cl: 0.32-0.92; P = .01)
Mos Since Randomization
17. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Most Common AEs With Approved
Targeted Agents in Advanced Melanoma
AE (≥ Grade 2), % Vemurafenib[1]
Dabrafenib[2]
Trametinib[3]
Arthralgia 21 5 NR
Rash 18 NR 27
Fatigue 13 6 9
Cutaneous SCC/
keratoacanthoma
12/8 6 (combined) NR
Hyperkeratosis 6 13 NR
Pyrexia NR 11 NR
Headache 5 5 NR
Photosensitivity (any grade) 12 3 NR
Hypertension NR NR 12
1. Chapman PB, et al. N Engl J Med. 2011;364:2507-2516. 2. Hauschild A, et al. Lancet. 2012;380:358-
365. 3. Flaherty KT, et al N Engl J Med. 2012;367:107-114.
18. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Vemurafenib + Ipilimumab: Hepatotoxicity
Phase I study in patients with BRAF V600–mutant
melanoma
– Dose-limiting grade 3 aminotransferase elevation in 4 pts
– Lowering dose of vemurafenib still produced elevated
aminotransferase levels
– Hepatic adverse events asymptomatic and reversible
– Other adverse events of the combination: grade 2 temporal
arteritis, grade 3 rash
– Study has been closed to further accrual
Ribas A, et al. N Engl J Med. 2013;368:1365-1366.
20. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Sosman J, et al. N Engl J Med. 2012;366:707-714.
BRIM-2 Phase II Study of Vemurafenib in
Metastatic Melanoma: PFSIndividualPatientsTreated
WithVemurafenib
TTP
Time to response
Died
Alive with response
Mos
0 202 4 6 8 10 12 14 16 18
21. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Molecular Characteristics of Disease
Progression
Variable restoration of signaling through ERK
No new activating mutations in BRAF
– BRAFV600E persists at progression
300
250
200
150
100
50
0
H-Score
BL Day 15 DP
pERK
Time
N = 23 n = 12
22. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Bypassing BRAF Inhibitor Blockade
Nazarian R, et al. Nature. 2010;468:973-977. Johannessen CM, et al. Nature. 2010;468:968-972. Villanueva J, et al. Cancer
Cell. 2010;18:683-695. Wagle N, et al. J Clin Oncol. 2011;29:3085-3096. Shi H, et al. Nat Commun. 2012;3:724. Poulikakos
PI,
et al. Nature. 2011;480:387-390. Straussman R, et al. Nature. 2012;487:500-504. Whittaker SR, et al. Cancer Discov. 2013;3:
350-362. Maertens O, et al. Cancer Discov. 2013;3:338-349.
CRAFBRAF
MEK
ERK
P
P
BRAF BRAF
BRAF
BRAF
NRAS
COT
MEK
Alternative splicing
Amplification
PI3K
NF1
23. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Single-Agent MEKi (Trametinib) in BRAF-
Mutant/BRAFi-Naive Metastatic Melanoma
Robert C, et al. ASCO 2012. Abstract LBA8509.
Disease Stage
39%
Trametinib (n = 214)
M1c
M1b
M1a
IIIC
Unknown
100
80
60
40
20
0
-20
-40
-60
-80
-100
%ChangeFromBaselinein
DiametersofTargetLesions
24. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Single-Agent MEK Inhibitor Has Minimal
Activity in BRAFi-Refractory Patients
Unconfirmed RR: 5% (95% CI: 0.6-16.9)
1 CR, 1 PR, 11 SD
*Discontinued prior BRAFi due to toxicity
K = V600K
M1cM1a M1bM Stage at Screening
K
K
K
K
*
MaximumReductioninTargetLesions
FromBaseline(%)
*
*
Kim KB, et al. J Clin Oncol. 2013;31:482-489.
100
80
60
40
20
0
-20
-40
-60
-80
-100
25. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Tumor Regression With BRAF/MEK
Combination in BRAFi-Refractory Patients
MaximumPercentReduction
FromBaseline
Mos Since
Prior BRAFi
PR
SD
PD
Best Response
on Prior BRAFiRR: 19%
M = Prior MEKi
Flaherty KT, et al. SMR 2011. Abstract LBA1-4.
--80
--60
--40
--20
0
20
40
1.0 0.4 0 0.6 4.2 -- 0.3 2.1 4.3 2.6 7.7 0.5 0.2 1.0 -- 6.2 0.5 1.0 0.2 7.4 9.21.1 1.1
M
M
M M
M
26. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Dabrafenib + Trametinib Combination in
BRAF Inhibitor–Naive Patients
MaximumPercentReductionFromBaselineMeasurement
Best Confirmed Response
CR
PRPD
SD
Dabrafenib 150 mg BID/Trametinib 2 mg QD
Long G et al. ESMO 2012. Abstract LBA27_PR.
100
80
60
40
20
0
-20
-40
-60
-80
-100
100
80
60
40
20
0
-20
-40
-60
-80
-100
Dabrafenib Monotherapy
27. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Delayed Resistance With BRAF/MEK
Combo vs Single-Agent BRAF Inhibition
Flaherty KT, et al. N Engl J Med. 2012;367:1694-1703.
Full-dose BRAF/MEK
Full-dose BRAF/half-dose MEK
Full-dose BRAF
Full-Dose BRAF/MEK Full-Dose BRAF
Median PFS, mos 9.4 5.8
HR 0.39 (P < .001)1.0
0.8
0.6
0.4
0.2
0
0 3 6 9 12 15 18
Mos Since Randomization
ProbabilityofPFS
28. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Grade 3†
All Grades Grade 3†
All Grades Grade 3†
All Grades
Cutaneous SCCa‡
9 (17) 10 (19) 1 (2) 1 (2) 3 (5) 4 (7)
Skin papilloma 0 8 (15) 0 4 (7) 0 2 (4)
Hyperkeratosis 0 16 (30) 0 3 (6) 0 5 (9)
Decreased EF 0 0 1 (2) 2 (4) 0 5 (9)
Cardiac failure 0 0 1 (2) 1 (2) 0 0
Hypertension 0 2 (4) 0 2 (4) 1 (2) 5 (9)
Chorioretinopathy 0 0 0 0 1 (2) 1 (2)
BRAF/MEK vs BRAF Inhibition: AEs
Flaherty KT, et al. N Engl J Med. 2012;367:1694-1703.
Adverse Event, n
(%)
Dabrafenib Monotherapy
(n = 53)*
Grade 3/4 All Grades
Combination 150/1
(n = 54)
Grade 3/4 All Grades
Combination 150/2
(n = 55)*
Grade 3/4 All Grades
Any event 23 (43) 53 (100) 26 (48) 53 (98) 32 (58) 55 (100)
Pyrexia 0 14 (26) 5 (9) 37 (69) 3 (5) 39 (71)
Chills 0 9 (17) 1 (2) 27 (50) 1 (2) 32 (58)
Fatigue 3 (6) 21 (40) 1 (2) 31 (57) 2 (4) 29 (53)
Nausea 0 11 (21) 2 (6) 25 (46) 1 (2) 24 (44)
Vomiting 0 8 (15) 2 (4) 23 (43) 1 (2) 22 (40)
Diarrhea 0 15 (28) 0 14 (26) 1 (2) 20 (36)
*1 patient assigned to monotherapy received combination 150/2 and was included in the combination 150/2 safety analyses.
†
No grade 4 adverse events reported for these categories.
‡
Includes keratoacanthoma .
29. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
BRAF “Inhibitors” Only Inhibit in the
Context of BRAF Mutation
CRAFBRAF
MEK
ERK
P
P
CRAF
MEK
ERK
P
P
CRAF
RAS-GTP
Heidorn SJ, et al. Cell. 2010;140:209-221. Poulikakos PI, et al. Nature. 2010;464:427-430.
Hatzivassiliou G, et al. Nature. 2010;464:431-435.
30. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
CRAFBRAF
MEK
ERK
P
P
CRAF
MEK
ERK
P
P
CRAF
RAS-GTP
BRAF
inhibitor BRAF
inhibitor
MEK
inhibitor MEK
inhibitor
Heidorn SJ, et al. Cell. 2010;140:209-221. Poulikakos PI, et al. Nature. 2010;464:427-430.
Hatzivassiliou G, et al. Nature. 2010;464:431-435.
BRAF “Inhibitors” Only Inhibit in the
Context of BRAF Mutation
31. clinicaloptions.com/oncology
A Unique Physician, Nurse, and Patient Seminar Series
Conclusions
For 50% of patients with melanoma, BRAF and MEK
inhibition have been validated as new therapies
Building on BRAF or BRAF/MEK inhibition will proceed in
2 directions:
– Further optimizing MAPK-targeted therapy
– Combination targeted therapy antagonizing pathways
essential for melanomagenesis
32. Go Online for More CCO
Coverage of Melanoma!
Interactive Case Challenges to compare your management decisions to
those of the expert faculty
Downloadable slides for your own noncommercial presentations or use
as a self-study resource
clinicaloptions.com/oncology
Editor's Notes
IC, inhibitory concentration.
CR, complete response.
BID, twice daily; IV, intravenously; PO, by mouth; q3 weeks, every 3 weeks; qd, daily.
BRAFi, BRAF inhibitor; MEKi, MEK inhibitor; PD, progressive disease; PR, partial response; RR, response rate, SD, stable disease.
Five patients had prior brain metastases (1 PR, 3 SD and 1 PD)
Three patients were V600K (1 PD, 2 SD)
Comments from Dr Falchook:
1. For each of the 3 patients who are not on the waterfall plot (mentioned at the bottom of the slide):
Did they come off study for clinical progression or toxicity? Or another reason?
What was their best response on a prior BRAFi?
What was the time since prior BRAFi?
2. How many of the PRs are confirmed?
3. There may not be room on the slide, but I would be interested to know the duration of treatment on the prior BRAFi for each patient, with an extra row at the bottom of the slide.
4. Again, there may not be room on the slide, but it would be nice to include which BRAFi each patient had received, as in slide 17.